Mitral Valve Surgery after Edge-to-Edge Repair

In last few years, transcatheter edge-to-edge repair (TEER) with MitraClip has been shown safe and effective, both for primary and secondary mitral valve regurgitation (MR), given the increasing interventionist and echocardiographer experience.    However, there is a group of patients that require surgery after failed TEER, either because of bad evolution or because device implantation is not feasible.  

Cirugía valvular mitral post tratamiento borde a borde

At present, there are no large studies on this population, and we do not know the impact of this etiology, be it primary or secondary, on outcomes.  In addition, there are no data on evolution after surgery.

The study looked at the CUTTING-EDGE Registry from 2009 to 2020, including 330 patients undergoing surgery after edge-to-edge repair. 155 (47%) had primary MR and 175 secondary MR. 

Inclusion criteria were: residual or significant MR, significant mitral stenosis, leaflet lesion, endocarditis, device detachment, device embolization or non-viable implantation.  

Mean age was 73 and 42% were women. 10.3% presented prior stroke, 15.8% peripheral vascular disease, 35.5% COPD, 4.2% dialysis, 56% pulmonary hypertension, 58.5% atrial fibrillation, and 26% prior cardiovascular surgery. STS was 4%. Most belonged in functional class III-IV.

Leia também: Provisional Stenting vs. Culotte: 5-Year Results of EBC TWO.

Secondary MR patients presented more CAD, diabetes, kidney function deterioration (41.3% vs. 62.3% p<0.0001 and pacemaker implantation.

Left ventricular ejection fraction was lower among secondary MR patients (41.1% vs 55.6% p<0.001).

Mean time from TEER to surgery time was 3.5 months and mostly because of: 33.6% recurrent MR, 28.8% residual MR, in; 25.2% loss of device insertion, 21.1% partial detachment, 14.5% mitral stenosis and 2.1% embolization. Mitral stenosis was more frequent among secondary MR patients (19.4% vs. 9% p=0.008).

In-hospital and 30-day mortality was 15.2% among primary MR patients and 16.7% in secondary MR patients. At 30 days there was a tendency towards higher mortality among secondary MR patients (20.4% vs. 12.7% p=0.07). There was no difference in hospital stay (13 days) or repeat hospitalization (6.2%), neither were there differences in hospital complications. 

Leia também: Impact of Right Ventricular Pacing in Patients with Permanent Pacemaker Implantation after TAVR.

At one year, global mortality was 31.3% global, and it was higher among secondary MR patients (38.3% vs. 23.2% p=0.01).

Actuarial cumulative survival rate after mitral valve surgery was 75.9% at one year and 68.3% at 3 years, and it was lower in secondary MR patients.

Mortality predictors at one year were: kidney failure, pre-operatory MR, emergency surgery, male sex, cirrhosis, tricuspid failure, and time off-pump.

Conclusion

Surgical risk after failed TEER is no trivial matter, seeing as it involves higher mortality, especially for patients with secondary MR. These findings provide valuable information for future research aiming at improving evolution. 

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Mitral Regurgitation Etiology on Mitral Surgery After Transcatheter Edge-to-Edge Repair. From de CUTTING-EDGE Registry.

Reference: Zaid, et al. J Am Coll Caridoll Intv 2023;16:1176-1188.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...